top of page

BOT

Botanix Pharmaceuticals Ltd

Pharmaceuticals

·

Healthcare

11

comments

6

fund managers

past 90 days

About Botanix Pharmaceuticals Ltd

Botanix Pharmaceuticals Ltd. is a dermatology company specializing in the research and development of antimicrobial and dermatological products. Headquartered in West Perth, Australia, the firm operates across markets in Australia and the United States. Founded in 1984 by Matthew Callahan, Roger New, and Glen Travers, Botanix focuses on advancing medical treatments within the dermatology sector. The company provides investors with insights into its clinical pipeline and operational activities across its primary geographical segments.

Commentary Volume

11

Comments

6

Fund managers

0

Past 90 days

SOURCE

ACTION

COMMENT PREVIEW

FUND MANAGER

DATE

Loading...

Source: Ipsum Capital Q4 Quarterly Letter  ·  Published 14 March 2025

Loading...

.

​Loading...

Loading...

Loading...

Loading...

Loading...

Source: Ipsum Capital Q4 Quarterly Letter  ·  Published 14 March 2025

Report a problem

Loading...

.

Loading...

Loading...

Loading...

Loading...

14 Mar 2025

ic

Ipsum Capital

"Lorem ipsum dolor sit amet...

Q4 Letter

14 Mar 2025

ic

Dolor Investments

"Lorem ipsum dolor sit amet...

Q4 Letter

🔒 21 more comments from 10 sources

Unlock full access

§ Important Notice

The entries below are records originating from third-party statements. Thesis Tracker does not rank, recommend or endorse any fund manager, fund or security. Investment decisions should be made on the basis of the relevant Product Disclosure Statement and, where appropriate, advice from a licensed adviser.

Commentary

Sector

Healthcare

Market cap

$61M

Fund managers

6 managers

First covered

31 May 2024

Last updated

1 Oct 2025

Company Details

Related Themes

ic

Ipsum Capital

6 comments

ic

Amet Funds

4 comments

ic

Dolor

3 comments

Top Investors Covering MIN

§ Reminder

The entries above are records originating from third-party statements. Thesis Tracker does not rank, recommend or endorse any fund manager, fund or security. Investment decisions should be made on the basis of the relevant Product Disclosure Statement and, where appropriate, advice from a licensed adviser.

Frequently asked questions about Botanix Pharmaceuticals Ltd (ASX:BOT)

Frequently asked questions

Who is investing in Botanix Pharmaceuticals Ltd (ASX:BOT)?

Fund managers including Salter Brothers, Monash Investors, SG Hiscock & Company, Firetrail Investments, Antares Capital and Lennox Capital Partners have invested in Botanix Pharmaceuticals Ltd (ASX:BOT).

What is the short interest in Botanix Pharmaceuticals Ltd (ASX:BOT)?

The short interest in Botanix Pharmaceuticals Ltd (ASX:BOT) is 3.09% which makes it the 77th most shorted stock on the ASX. Of the 2.0B shares that Botanix Pharmaceuticals Ltd has on issue, 60.9M have been sold short.

What does Botanix Pharmaceuticals Ltd (ASX:BOT) do?

Botanix Pharmaceuticals Ltd. is a dermatology company specializing in the research and development of antimicrobial and dermatological products. Headquartered in West Perth, Australia, the firm operates across markets in Australia and the United States. Founded in 1984 by Matthew Callahan, Roger New, and Glen Travers, Botanix focuses on advancing medical treatments within the dermatology sector. The company provides investors with insights into its clinical pipeline and operational activities across its primary geographical segments.

bottom of page